Sunday, November 12, 2023
- 9:00AM-11:00AM
-
Abstract Number: 0215
Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
(0196–0228) Infection-related Rheumatic Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 0497
Effects and Tolerability of Low to Moderate Biomechanical Stress During Leisure Sport Activity in Patients with Psoriasis and Psoriatic Arthritis
(0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA- 9:00AM-11:00AM
-
Abstract Number: 0531
Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis
(0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I- 9:00AM-11:00AM
-
Abstract Number: 0434
Effects of B/tsDMARDs on Non-inflammatory Pain in Patients with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-
(0423–0459) RA – Treatments Poster I- 9:00AM-11:00AM
-
Abstract Number: 0688
Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)
(0673–0690) Vasculitis – ANCA-Associated Poster I: Treatment Outcomes- 9:00AM-11:00AM
-
Abstract Number: 0244
Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I- 9:00AM-11:00AM
-
Abstract Number: 0685
Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
(0673–0690) Vasculitis – ANCA-Associated Poster I: Treatment Outcomes- 9:00AM-11:00AM
-
Abstract Number: 0674
Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis
(0673–0690) Vasculitis – ANCA-Associated Poster I: Treatment Outcomes- 9:00AM-11:00AM
-
Abstract Number: 0372
Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial
(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA- 9:00AM-11:00AM
-
Abstract Number: 0597
Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study
(0582–0608) SLE – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0608
Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study
(0582–0608) SLE – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0524
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
(0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I- 9:00AM-11:00AM
-
Abstract Number: 0716
Efficacy of Immunosuppressants for Disease Relapse in Patients with IgG4-related Disease at Our Institution
(0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I